key: cord-0765492-t9xihpf8 authors: Izikson, R.; Brune, D.; Bolduc, J.-S.; Bourron, P.; Fournier, M.; Mallett Moore, T.; Pandey, A.; Perez, L.; Sater, N.; Shrestha, A.; Wague, S.; Samson, S. I. title: Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults >= 65 years of age: a Phase II, open-label study date: 2021-10-29 journal: nan DOI: 10.1101/2021.10.29.21265248 sha: ed8350f187beca4ed2f368551d3ba544b1aaf7ee doc_id: 765492 cord_uid: t9xihpf8 Background Concomitant seasonal influenza vaccination with a COVID-19 vaccine booster could help to minimise potential disruption to the seasonal influenza vaccination campaign and maximise protection against both diseases among individuals at risk of severe disease and hospitalisation. This study assesses the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and a mRNA-1273 vaccine booster dose in older adults. Methods This is an ongoing Phase II, multi-centre, open-label study (NCT04969276). We describe interim results up to 21 days after vaccination (July 2021-August 2021). Adults aged [≥] 65 years living in the community, who were to have received a second mRNA-1273 dose at least five months previously, were randomised (1:1:1) to concomitant QIV-HD and mRNA-1273 vaccination (Coad), QIV-HD alone, or mRNA-1273 vaccine alone. Unsolicited adverse events (AEs) occurring immediately, solicited local and systemic reactions up to day (D)8, and unsolicited AEs, serious AEs (SAEs), AEs of special interest (AESIs) and medically attended AEs (MAAEs) up to D22 were reported. Haemagglutination inhibition (HAI) antibody responses to influenza A/H1N1, A/H3N2, B/Yamagata and B/Victoria strains and SARS CoV-2 binding antibody responses (SARS-CoV-2 Pre-Spike IgG ELISA) were assessed at D1 and D22. Findings Of 306 participants randomised, 296 were included for analysis (Coad, n=100; QIV-HD, n=92; mRNA-1273, n=104). Reactogenicity profiles were similar between the Coad and mRNA-1273 groups, with lower reactogenicity rates in the QIV-HD group (frequency [95% CIs] of solicited injection site reactions: 86{middle dot}0% [77{middle dot}6-92{middle dot}1], 91{middle dot}3% [84{middle dot}2-96{middle dot}0] and 61{middle dot}8% [50{middle dot}9-71{middle dot}9] ; solicited systemic reactions: 80{middle dot}0% [70{middle dot}8-87{middle dot}3], 83{middle dot}7% [75{middle dot}1-90{middle dot}2] and 49{middle dot}4% [38{middle dot}7-60{middle dot}2], respectively). Up to D22, unsolicited AEs were reported for 17{middle dot}0% and 14{middle dot}4% participants in the Coad and mRNA-1273 groups, respectively, with a lower rate (10{middle dot}9%) in the QIV-HD group. Seven MAAEs were reported (Coad, n=3; QIV-HD, n=1; mRNA-1273, n=3). There were no SAEs, AESIs or deaths. HAI antibody geometric mean titres (GMTs) increased from D1 to D22 to similar levels for each influenza strain in the Coad and QIV-HD groups (GMTs [95% confidence interval], range across strains: Coad, 286 [233-352] to 429 [350-525] ; QIV-HD, 315 [257-386] to 471 [378-588]). SARS-CoV-2 binding antibody geometric mean concentrations (GMCs) also increased to similar levels in the Coad and mRNA-1273 groups (D22 GMCs [95% confidence interval]: 7634 [6445-9042] and 7904 [6883-9077], respectively). Interpretation No safety concerns or immune interference were observed for concomitant administration of QIV-HD with mRNA-1273 booster in adults aged [≥] 65 years, supporting co-administration recommendations. Influenza is an acute viral respiratory disease that affects all age groups, but with a disproportionate 54 disease burden in older adults. Previous global modelling estimates have provided influenza-55 associated respiratory excess mortality rates of 0·1 to 6·4 per 100 000 individuals for people younger 56 than 65 years, 2·9 to 44·0 per 100 000 individuals for people aged between 65 and 74 years, and 17·9 57 to 223·5 per 100 000 for people older than 75 years. 1 Beyond respiratory-related disease, broader non-58 respiratory consequences of influenza add significant disease burden, including exacerbation of 59 chronic underlying conditions, increased susceptibility to secondary microbial infections, 60 cardiovascular events, and functional decline. 2 Seasonal influenza vaccination reduces influenza-associated morbidity and mortality in groups at 62 increased risk for complications including older adults. 3, 4 A high-dose influenza vaccine, which 63 provided guidance on the concomitant administration of influenza and COVID-19 vaccines, with the 107 aim of shortening the vaccination period, reducing the number of visits to healthcare providers, and 108 minimising missed opportunities to immunise against influenza. 31-36 109 The current study describes safety and immunogenicity following concomitant administration of QIV-110 HD and a third (booster) dose of mRNA-1273 vaccine in adults aged ≥ 65 years in the USA. 111 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint This is an ongoing Phase II, multi-centre, open-label, descriptive study (ClinicalTrials.gov: 114 NCT04969276), conducted in six sites in the USA. The study was initiated on 16 July 2021 and has a 115 planned completion date of 15 February 2022, and included: an active phase, from D1 (enrolment, 116 pre-vaccination blood draw and vaccination) through D22 (post-vaccination blood draw), and a six-117 month safety follow up (D181). Completion of the active phase of the study, reported here, was on 31 118 August 2021. 119 Community-dwelling adults aged ≥ 65 years, previously vaccinated with a two-dose primary schedule 120 of the mRNA-1273 vaccine, were eligible for inclusion. The second dose of the primary mRNA-1273 121 vaccination series was required to have been received at least five months before enrolment in the 122 study. Individuals with immunodeficiency, or who had received immunosuppressive therapy 123 (preceding six months) or long-term systemic corticosteroid therapy, or who had thrombocytopenia or 124 received anticoagulants in the three weeks preceding inclusion, were excluded from the study. Other 125 exclusion criteria included any vaccination in the four weeks preceding the study, or planned receipt 126 of any vaccine between D1 and D28. 127 The study conduct is in compliance with the International Council for Harmonisation Good Clinical 128 Immunology, Sanofi Pasteur laboratory (Swiftwater, PA, USA), as described previously. 37 The 152 endpoint of the assay is the highest serum dilution in which complete inhibition of haemagglutination 153 occurs. The lower limit of quantification was 1:10. Titres below this level were reported as <10 154 The SARS-CoV-2 Pre-Spike IgG enzyme-linked immunosorbent assay was a validated assay, 156 performed by Nexelis (Laval, Quebec, Canada) as previously described. 38 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. analyses were carried out to assess the ratios of post-vaccination GMTs or GMCs, between the Coad 176 and single administration groups, for each influenza strain and for the SARS-CoV-2 antigen. 177 All analyses were descriptive. A total of 300 participants (approximately 100 per treatment group) 179 were planned for enrolment. Safety endpoints were described for each study intervention group in the 180 safety analysis set (SafAS; all participants who received at least one dose of the study vaccine). 181 Immunogenicity endpoints were described for each study intervention group in the immunogenicity 182 analysis set (IAS; subset of randomised participants who received at least one dose of study vaccine). 183 All analyses were performed according to the vaccine(s) actually received. For the immunogenicity 184 results, 95% confidence intervals (CIs) for the point estimates were calculated using the normal 185 approximation after log transformation for quantitative data (GMC and geometric mean [GM] of 186 individual ratios) and exact binomial distribution (Clopper-Pearson method, quoted by Newcombe) 187 for single proportions. For the ratios of post-vaccination GMTs or GMCs between Coad and single 188 administration groups, a baseline adjustment was applied using an ANCOVA model of the D22 log 10 189 titre/concentration with vaccine group and D01 log 10 titre as factor and covariate, respectively. 190 Funding was provided by Sanofi Pasteur. Sanofi Pasteur was involved in the study design, data 192 collection, data analysis, data interpretation, writing of the report, and the decision to submit the paper 193 for publication. This work was carried out in collaboration with Moderna (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint A total of 306 participants were enrolled and randomised, of whom 296 received at least one vaccine 200 dose (Coad, n=100; QIV-HD, n=92; mRNA-1273, n=104). A total of 293 participants completed the 201 active phase (through D22); 11 withdrew (Coad group, n=1 QIV-HD group, n=10) and one (QIV-HD) 202 discontinued due to a protocol deviation (Supplementary Figure 1) . The higher number of 203 withdrawals in the QIV-HD group was due to participants who had wanted to receive a COVID-19 204 vaccine discontinuing from the study once they were not randomised to receive mRNA-1273. One 205 participant randomised to the mRNA-1273 group was mistakenly administered both the QIV-HD and 206 mRNA-1273 vaccine and was therefore included in the Coad group for safety and immunogenicity 207 analyses. Overall, in the SafAS, there were more female (166/296 [56·1%]) than male participants, 208 particularly in the mRNA-1273 group ( Table 1) . The mean age of participants was 72 years; 71/296 209 (24·0%) participants were ≥ 75 years old and the age distribution was balanced between treatment 210 groups. Most participants (282/296 [95·3%]) were white and were non-Hispanic or Latino; and most 211 had received seasonal influenza vaccination the previous season (2020-2021) ( Table 1) . The 212 characteristics of participants in the IAS were comparable to those in the SafAS (data not shown). 213 Four immediate unsolicited AEs were reported: three by one participant in the Coad group (anxiety 215 and dizziness, both grade 1 intensity and resolved spontaneously in one day; and grade 3 216 hypertension, which resolved by D10) and one in a participant in the QIV-HD group (dizziness, grade 217 1 intensity and assessed by the investigator as related to study vaccination; resolved spontaneously 218 after one day) (Supplementary Table S1 Table S1 ). Injection site pain was the most frequently reported 224 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint solicited injection site reaction in each treatment group; the most frequently reported grade 3 injection 225 site reactions were pain (ranging between 0 and 4·0% per group) and erythema (ranging between 0 226 and 6·7%) ( Figure 1A) . Solicited systemic reactions were also reported at a similar rate between the 227 Table 1 Immunogenicity 251 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For each influenza strain, HAI GMTs were similar across all groups at baseline (D1), and increased 253 post-vaccination at D22 to similar levels in the Coad and QIV-HD groups. Post-vaccination HAI 254 GMTs remained close to baseline levels in the mRNA-1273 group as expected (Figure 2A) . D22 255 GMT ratios relative to baseline are presented in Table 2 . From D1 to D22 the proportion of 256 participants with HAI titres ≥ 40 for each strain increased in the Coad and QIV-HD groups, to similar 257 levels between the two groups (Figure 3) . Seroconversion rates were similar between the Coad and 258 QIV-HD groups for each strain ( Table 2) . 259 HAI GMT ratios between the Coad and QIV-HD groups at D22 were 0·87 (95% CI 0·61-1·23) for 260 H1N1, 0·89 (95% CI 0·70-1·14) for H3N2, 0·88 (95% CI 0·71-1·09) for B/Yamagata and 0·96 (95% 261 CI 0·79-1·16) for B/Victoria. 262 Table 2) . 268 The SARS-CoV-2 anti-S binding IgG GMC ratio between the Coad and mRNA-1273 groups at D22 269 was 0·97 (95% CI 0·79-1·19). 270 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. showed that the coadministration of a second dose of the SARS-CoV-2 mRNA vaccine BNT162b2 298 (Pfizer/BioNTech) with one of three seasonal inactivated influenza vaccines had acceptable 299 reactogenicity and tolerability, with no evidence of negative immune interference compared with 300 administration of each vaccine alone. 45 Based on those preliminary data, the UK government updated 301 their guidance to support concomitant administration of the BNT162b2 vaccine with influenza 302 vaccines (in separate arms) 46 and encourages concomitant administration of the influenza vaccine with 303 COVID-19 booster vaccination, where practical to do so. 34 304 To our knowledge, this study provides the first data supporting concomitant administration of QIV-305 HD with a COVID-19 booster vaccine dose in older adults. Our data thus provide additional insights 306 that support current public health recommendations to implement seasonal influenza vaccination 307 concomitantly with COVID-19 booster vaccination. This will help to avoid delays in influenza 308 vaccination during the upcoming NH influenza season, particularly among those at increased risk of 309 waning protection from COVID-19 and increased risk of severe illness and hospitalisation due to both 310 This study employs previously validated assays to measure HAI antibody responses 37 CoV-2 Pre-Spike IgG antibody responses. 38 High influenza HAI antibody titres were observed pre-313 vaccination, especially for the influenza B strains. This may be due to the fact that this study 314 population was vaccinated very early in the influenza season (July-August) and that the same B 315 strains were used in the 2020-2021 and 2021-2022 vaccine compositions; moreover, greater than 316 90% of the subject population had received influenza vaccine in the prior season. Despite the fact that 317 we included approximately 100 participants in each intervention group, this study was not powered 318 for statistical comparisons between study groups. Furthermore, the dose of mRNA-1273 (100 µg) is 319 greater than the dose (50 µg) that has recently been authorised for a booster dose. In the absence of 320 increase in incidence or severity of AEs and ARs and without evidence of interference in the immune 321 response, the results of this study should enable extrapolation to coadministration of lower doses with 322 longer intervals between the second and third dose. Notably, the study population did not sufficiently 323 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint represent the ethnic and racial diversity of the US population. This was in part due to the very short 324 time window for enrolment of study participants (approximately two weeks), but should be prioritised 325 and improved in future studies. 326 Our findings suggest that QIV-HD and the mRNA-1273 vaccine can be administered together without 327 evidence of any safety concern or interference in the immune response, thus supporting existing 328 guidance on the implementation of concomitant vaccination campaigns against both influenza disease 329 and COVID-19. 330 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Qualified researchers may request access to patient level data and related study documents including 344 the clinical study report, study protocol with any amendments, blank case report form, statistical 345 analysis plan, and dataset specifications. Patient level data will be anonymised and study documents 346 will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing 347 criteria, eligible studies, and process for requesting access can be found at: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Data shown are n (%) unless specified otherwise. SD, standard deviation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint Footnote: GMC, geometric mean concentration. GMT, geometric mean titre. HAI, haemagglutinin inhibition. Error bars show 95% confidence intervals. Annotations above each bar indicate GMTs (A) or GMCs (B) for each group/time point. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint Post-/pre-dose GMCR: 13.7 (95% CI 11.2-16.8) 0.88 (95% CI 0.75-1.03) 14.2 (95% CI 12.0-16.9) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 29, 2021. ; https://doi.org/10.1101/2021.10.29.21265248 doi: medRxiv preprint Estimates of global seasonal influenza-associated respiratory mortality: a modelling study The disease burden of influenza beyond respiratory illness Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices -United States, 2017-18 Influenza Season Vaccination in the elderly: The challenge of immune changes with aging Efficacy of high-dose versus standard-dose influenza vaccine in older adults Introductory paper: High-dose influenza vaccine New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults -United States Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine COVID-19 vaccine tracker Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) Covid-19 in Israel Countries weigh need for booster COVID-19 shots Recommended composition of influenza virus vaccines for use in 36. World Health Organization. Coadministration of seasonal inactivated influenza and COVID-19 vaccines: Interim guidance Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebocontrolled, phase 1-2, dose-ranging study Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older Emergency Use Authorisation (EUA) Prescribing Information. Fact sheet for healthcare providers administering vaccine (vaccination providers) The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV) UK Medicines & Healthcare Products Regulatory Agency. Information for Healthcare Professionals on COVID-19 Vaccine Pfizer/BioNTech (Regulation 174)